Abstract: Objective  To evaluate the efficacy and safety of icotinib combined with radiotherapy in the treatment of lung cancer with brain metastasis. Methods  The Cochrane Library,  PubMed,  EMbase, CBM, VIP, CNK and WanFang Data were searched for the references on icotinib combined with radiotherapy in the treatment of lung cancer with brain metastases published from the date of January 2011 to July 2017. According to the inclusion and exclusion criteria,  two reviewers  screened the studies  independently,  extracted the data and assessed the quality. Then, RevMan 5.3 software was used for meta analysis.Results  A total of 5 clinical control studies involving 281 patients were included. The results of metaanalysis showed that  icotinib combined with radiotherapy may contribute to higher CR as compared with the group treated with radiotherapy only(OR=2.69, 95%CI=1.305.58, P=0.008) and PR (OR=2.28, 95%CI=1.403.71, P=0.0009) rates,  ORR(OR=4.16, 95%CI=2.267.67, P=0.00001), and DCR
(OR=3.97, 95%CI=1.709.26, P=0.001), and lower PD(OR=0.30, 95%CI=0.140.62, P=0.001) and SD (OR=0.39, 95%CI=0.220.69,P=0.001) rates for lung cancer patients with brain metastases. Moreover, the group of icotinib combined with radiotherapy increases the risk of erythra (OR=6.79, 95%CI=3.4013.55, P<0.05) and diarrhea (OR=2.57, 95%CI=1.096.04, P=0.03). There were no significant differences in leukopenia (P=0.70),  nausea and vomiting(P=0.20), and liver function impairment(P=0.32，P>0.05) between the two groups.Conclusion  Icotinib combined with radiotherapy is more effective than monotherapy for lung cancer with brain metastasis. Meanwhile, the group of icotinib combined with radiotherapy increases the risk of erythra and diarrhea which can be alleviated after expectant treatment. There were no significant differences between the two groups in leukopenia,  nausea and vomiting, liver function impairment. The therapy is safe and reliable.

Key words: lung neoplasms, brain metastases; , icotinib, chemoradiotherapy, metaanalysis